ClinicalTrials.gg
RecruitingNCT07509892Updated Jul 8, 2026

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

A Phase 2 interventional study of TQH3906 capsule and TQH3906 placebo in Systemic Lupus Erythematosus, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 35 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
42nd of 245
198 · median 36
Started
2026
with 55 others
Phase 2
33 of 266
14 open now
Primary completion
2027-11
later than 122 of 190 live
Registered
242nd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 42nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 122 of the 190 other live ones, and was the 242nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign a written form, which must meet the following requirements:

    • Willingness to participate in the study and ability to sign an informed consent form.
    • Willingness and ability to complete all research-related procedures and site visits.
  • Characteristics of participants in the Systemic Lupus Erythematosus (SLE) trial:

    • Screen for patients with a confirmed diagnosis of SLE dating back to at least 24 weeks prior to the visit.
    • Diagnosed with systemic lupus erythematosus according to the 2019 classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
    • Meet one of the following criteria: elevated levels of antinuclear antibodies (ANA) ≥ 1:80, positive results for anti-double-stranded DNA (anti-dsDNA) (positive results include indeterminate results), or positive results for anti-Smith (anti-Sm) antibodies.
    • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) score ≥ 8 and clinical SLEDAI-2K score ≥ 4, with involvement of joints and/or skin vasculitis and/or rash manifestations (Note: Clinical SLEDAI-2K manifestations do not include complement deficiency and positivity for anti-ds-DNA antibodies).
  • Age between 18 and 75 years old (based on the date of signing the informed consent form).
  • Medications for SLE treatment:

    • Prior to the screening visit, there must be a period of background therapy of at least 12 weeks. The therapy must have been administered at a stable dose for at least 4 weeks prior to the screening visit and remain stable until randomization and throughout the duration of the study participation. If antimalarial or therapy is discontinued prior to the screening visit, the last dose must have been administered at least 4 weeks prior. Detailed information on specific medications is as follows:

      1. Immunosuppressants (can be used only one type; combination use is not permitted): Antimalarial drugs: Hydroxychloroquine (allowed for monotherapy; allowed in combination with one type of immunosuppressant) (maximum 400 mg/day).
      2. Duration of clearance when using other immunomodulatory drugs or biologics.
    • (CS) (prednisone or equivalent medication) is permitted but not required as background therapy. For trial participants using CS, the dose must be stable for at least 2 weeks prior to the screening visit, not exceed 40 mg/day during screening, and remain stable prior to randomization. Monotherapy with CS is not permitted.
    • The requirements for trial participants currently receiving long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are as follows:

      1. The dosage must remain stable for a period of 14 days prior to the screening visit and must remain stable until randomization and throughout the study period. The use of NSAIDs alone is not permitted.
      2. A maximum of one oral NSAID (at a stable dosage) may be used during the study period.
      3. The concurrent use of aspirin as a cardiovascular protective agent/to prevent thrombosis (in addition to other NSAIDs) is permitted throughout the study period, provided that the dosage remains stable.
  • Women of childbearing age must agree to use effective measures during the study period and for 6 months thereafter, and undergo a blood pregnancy test that is negative within 7 days prior to enrollment in the study. Men must agree to use effective contraceptives during the study period and for the subsequent 6 months.

Exclusion criteria

Exclusion Criteria:

  • Conditions other than SLE:

    • drug-induced SLE;
    • Trial participants with other diseases (e.g. multiple sclerosis, psoriasis, inflammatory bowel disease, etc.) were excluded. Test participants with secondary dry syndrome could not be excluded;
    • Excluded trial participants with overlapping syndromes of SLE, such as systemic sclerosis and mixed associative weaving disease;
    • In the case of a combination of antiphospholipid syndrome secondary to systemic lupus erythematosus, prior severe blood clots / obstetric complications need to be ruled out; Prophylaxis with low-dose aspirin (50-100 mg / d) in the absence of thrombotic events or obstetric comorbidities and with high-risk antiphospholipid antibody (aPL) characteristics may be included;
    • Trial participants who had had lupus encephalopathy before screening were excluded;
    • Excluding active, severe lupus nephritis requiring cytotoxic drugs (CTX) or high-dose CS treatment, excluding lupus pinocytosis, thrombotic microangiopathy; Trial participants with lupus nephritis, but who are currently controlled, may be included;
  • Other medical conditions and medical history;

    • Study participants who are pregnant or breastfeeding;
    • Evidence of a significant disease / condition or unstable clinical condition (e.g. kidney, Liver, blood, gastrointestinal, endocrine, lung, immune, psychiatric) or locally active infection / infectious disease which, according to medical judgement, will significantly increase the risk of the trial participants if they participate in the study;
    • Have had any major surgery within 30 days prior to the first dose of the study treatment, or planned to have any surgery during the course of the study;
    • Cancer or a history of cancer or lymphotrophic disease within the past 5 years (except adequately treated basal cell carcinoma or squamous cell carcinoma with no evidence of recurrence);
    • Class III or IV congestive heart failure as defined by the (NYHA) or any recent episode of heart failure resulting in symptoms of NYHA Class III / IV; Or a history of ventricular arrhythmia (e.g. persistent ventricular arrythmia , ventricular tremor, sharp twisted ventricular articular arrhythmia) or an arrhythmia that requires continuous anti-arrhythmic medication;
    • A history of acute coronary syndrome (e.g. myocardial infarction, unstable angina) and / or any major cerebrovascular disease within 24 weeks prior to screening;
    • Currently or recently (within 3 months prior to randomization) had a gastrointestinal disease, including gastrointestinal surgery, that was likely to affect treatment absorption in the study;
    • In medical judgment, the trial participants had non-SLE concomitant conditions that may require additional systemic therapy during the study (e.g., asthma);
    • Severe blood loss (> 500 mL) or transfusion within 4 weeks prior to randomization;
    • It is not possible to take the drugs orally;
    • Unable to receive venous punctures and / or tolerate venous pathways;
    • Persons who have a history of substance abuse and cannot quit or who have psychiatric disorders;
    • Any other medical, spiritual and / or social reasons determined by medical judgement;
  • Previous and combined drug use:

    • Unable to adhere to restricted and prohibited treatments; Unable to comply with the discontinuation requirement;
    • Use more than one ;
    • Previous exposure to other TYK2 inhibitors;
    • Participants who were previously exposed to anti-interferon targeted drug trials such as Anilumab, Rontalizumab, nterferon Alpha Kinoid (INFaKinoid), etc.;
    • Other research drugs must be discontinued for at least 12 weeks or 5 half-lives (whichever is longer) before screening.
  • Infection Related:

    • Chest radiology within 6 months prior to screening showed the presence of active Tuberculosis (TB) in the trial participants. Test participants who were negative for chest radiology within 3 months prior to screening were eligible to participate in the study:
    • , , or (HIV) infection, characterized by antibodies to hepatitis C (anti-HCV) and all HCV-RNA positive, surface antigens to hepatitis B (HBsAg) positive, core antibodies to the hepatitis A (HBcAb) and all HIV-DNA positive, or HIV antibody screening positive;
    • is currently receiving any treatment regarding chronic infections;
    • Persons in need of treatment for syphilis;
    • Have a congenital or acquired immunodeficiency disorder;
    • Have a history of repeated infections requiring hospitalization or treatment outside the bowel (muscle or intravenous) and receiving intravenous antibiotics; Or need to be hospitalized and / or given intravenous anti-infective treatment within 30 days of the random, or receive any infection requiring oral anti-infectious treatment within 14 weeks of the random;
    • Prior history of systemic shingles; Or have two or more recurrent shingles in two years; Or the shingles infection did not completely subside within 12 weeks prior to screening;
    • Vaccinated live within 90 days of randomization or inactivated within 30 days of randomisation;
  • Abnormalities in physical or laboratory tests:

    • Clinically significant chest X-ray or abnormalities
    • A laboratory test of clinical significance is abnormal. A screening period laboratory test with abnormal results may be repeated once to confirm abnormal results. If the results are restored to programme acceptable during the screening period without intervention, trial participants may be admitted to the study;
    • Any other significant laboratory abnormalities that may, in medical judgement, pose an unacceptable risk to the trial participants during the study period;
  • Other exclusion criteria:

    • Have a history of any significant drug allergy (e.g. causing an allergic reaction or causing liver toxicity); He is known to be allergic to the ingredients of research drugs;
    • those who are unable to comply with the pilot programme;
    • Persons who are ready to undergo or have previously undergone a heterotopic bone marrow transplant or a solid organ transplant;
    • In the judgement of the investigator, there is a situation that seriously endangers the safety of the test participants or affects the completion of the study by the test participant.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    16 mg TQH3906 capsule

    16 mg TQH3906 capsule, oral administration, once daily, for a duration of 48 weeks.

    Drug: TQH3906 capsule

  • Experimental
    24 mg TQH3906 capsules

    24 mg TQH3906 capsule, oral administration, once daily, for a duration of 48 weeks.

    Drug: TQH3906 capsule

  • Placebo comparator
    TQH3906 placebo

    Placebo, oral administration, once daily, for a duration of 48 weeks.

    Drug: TQH3906 placebo

Interventions

  • The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor.

  • DrugTQH3906 placebo

    Placebo without drug.

06

What researchers measure

Primary outcomes

  1. The percentage of participants who achieved Systemic Lupus Erythematosus Responder Index 4 (SRI-4)

    The percentage of trial participants who reached SRI-4 by week 32.

    Time frame: Baseline to week 32.

Secondary outcomes

  1. The percentage of participants who achieved SRI-4

    The percentage of trial participants who reached SRI-4 by weeks 24 and 48

    Time frame: Baseline to week 24, baseline to week 48

  2. Percentage of trial participants achieving composite lupus assessment (BICLA) remission based on the British Isles Lupus Assessment Group (BILAG) index

    Percentage of trial participants achieving composite lupus assessment according to the British Isles Lupus Assessment Group (BILAG) index by weeks 24, 32, and 48 (BICLA remission)

    Time frame: Baseline to week 24, baseline to week 32, baseline to week 48

  3. The percentage of trial participants who achieved low disease activity status (LDA) for lupus

    The percentage of trial participants who achieved low disease activity status (LDA) for lupus by weeks 24, 32, and 48

    Time frame: Baseline to week 24, baseline to week 32, baseline to week 48

  4. The proportion of trial participants with baseline Clinical Lupus Activity Index (CLASI) activity score ≥ 10 and achieving CLASI response (defined as a reduction in CLASI activity score of ≥ 50% from baseline at weeks 24, 32, and 48)

    The proportion of trial participants with baseline Clinical Lupus Activity Index (CLASI) activity score ≥ 10 and achieving CLASI response (defined as a reduction in CLASI activity score of ≥ 50% from baseline at weeks 24, 32, and 48)

    Time frame: Baseline to week 24, baseline to week 32, baseline to week 48

  5. The percentage of trial participants who achieved a joint count of 50 (defined as having ≥ 6 joints affected at baseline and a reduction in joint involvement of ≥ 50% from baseline)

    Percentage of trial participants who achieved a joint count of 50 (defined as having ≥ 6 joints affected at baseline and a reduction in joint involvement of ≥ 50% from baseline) by weeks 24, 32, and 48

    Time frame: Baseline to week 24, baseline to week 32, baseline to week 48

07

Study locations

2 of 35 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2027, 17 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2026
First posted
Apr 3, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Mar 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07509892
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Jun 22, 2026
Primary completion
Nov 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Zhanguo Li, Doctor
Contact
li99@bjmu.edu.cn
13910713924

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH3906

Start the discussion